Curcumin has become a focus of interest with regard to its antitumor effects in prostate cancer; however, the effects of this agent on invasion and metastasis remain less well understood. Matrix metalloproteinases (MMPs) are important prerequisite for tumor invasion and metastasis. In this study, we evaluated the effects of curcumin on prostate cancer cells (DU-145) invasion in both in vitro and in vivo. We utilized zymography and ELISA in order to determine the MMP-2 and MMP-9 activity. Matrigel invasion assay was performed to assess cellular invasion. We developed a xenograft model to examine tumorigenicity. Curcumin treatment resulted not only in a significant reduction in the expression of MMP-2 and MMP-9, but also effected the inhibition of invasive ability in vitro. Curcumin was shown to induce a marked reduction of tumor volume, MMP-2, and MMP-9 activity in the tumor-bearing site. The metastatic nodules in vivo were significantly fewer in the curcumintreated group than untreated group. Curcumin appears to constitute a potential agent for the prevention of cancer progression, or at least of the initial phase of metastasis, in prostate cancer.
Introduction
In 2004, prostate cancer alone accounted for approximately 33% (230 110) of all new cancer cases among men in the United States. In addition, 29 900 cancer deaths are expected to result from prostate cancer this year, making it the second leading cause of cancer death in males. 1 Although the prevalence of latent or indolent prostate cancer does not appear to differ greatly throughout the world, the occurrence rates of clinically significant prostate cancer and mortality rates do differ significantly between Asian and Western populations. This difference has been proposed to be attributable to the dietary consumption of abundant amounts of plant-based foods in Asia, foods that are often also rich in phytochemicals. 2, 3 The majority of prostate cancer deaths occur in patients exhibiting metastases. In order to metastasize, degradation of the extracellular matrix (ECM) and basement membrane must occur. The matrix metalloproteinases (MMPs) constitute a family of zinc-dependent endopeptidases, which degrade several components of the ECM. 4 Among the MMPs, a great concern has focused on MMP-2 and MMP-9. These MMPs have been demonstrated to degrade type IV collagen, and have also been shown to be involved in the invasion, angiogenesis, and metastasis of tumor cells. 5, 6 Previous studies have reported the existence of an intimate relationship between tumor progression and MMPs expression in cases of human prostate cancer. [7] [8] [9] [10] [11] Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptane-3,5-dione) is the principal ingredient of the turmeric compounds extracted from the rhizomes of the plant, Curcuma Longa, which is indigenous to Indian and Southeast Asian environs. The results of previous studies have revealed that curcumin exerts pleiotropic effects on prostate cancer cells; however, its functions in invasion and metastasis have yet to be clearly elucidated. [12] [13] [14] [15] [16] [17] [18] Therefore, we assessed the effects of curcumin on the in vitro invasion of prostate cancer cells (DU-145), and further attempted to determine, using a tumor xenograft model, whether curcumin effected an inhibition of prostate cancer cell invasiveness.
Materials and methods
In vitro study Cell culture and material. The androgen-independent prostate cancer cell line, DU-145, was acquired from the American Type Culture Collection (Rockville, MD, USA).
The cells were maintained in Roswell Park Memorial Institute (RPMI)-1640 medium, which had been supplemented with 10% fetal bovine serum (FBS), at 371C in a humidified atmosphere containing 5% CO 2 and 95% air. The cells were grown until 60-80% confluence was achieved.
The curcumin (X95% purity) was obtained from the Sigma-Aldrich Co. (St Louis, MO, USA). A 10 mg/ml curcumin solution was prepared with 95% ethanol, and then diluted further in cell culture medium.
Cell proliferation and viability. The DU-145 cells were seeded at a number of 1 Â 10 3 cells/well, in flatbottomed, 96-well tissue culture plates. After 24 h of incubation to allow the cells to adhere, the culture medium was extracted, and was replaced with 0.2 ml of medium harboring a variety of curcumin concentrations, ranging from 0.5 to 120 mg/ml. The cells were then incubated for 24, 48, and 72 h, at 371C, in an atmosphere containing 5% CO 2 in air. At the end of the incubation, we added a 20 ml aliquot of 5 mg/ml MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich Co, St Louis, MO, USA) to each of the wells. After 4 h of incubation at 371C, formazan crystals were dissolved in 50 ml of dimethyl sulfoxide. We then measured absorbance at a wavelength of 540 nm, using a microplate reader (Molecular Devices, Sunnyvale, CA, USA). The percentage of viability was determined as a fraction of the loss of cell viability in the cultures. Each of the assays was conducted in quadruplicate.
Caspase-3 assay. The DU-145 cells (2 Â 10 4 cells) were grown to confluence in culture dishes. The DU-145 cells were treated with 10 mg/ml of curcumin for 0, 12, 24, and 48 h. The supernatant was removed and discarded while the cell pellet was lysed by the addition of lysis buffer. The cell lysates were then processed in accordance with the manufacturer's instructions provided in the Caspase-3 Colorimetric Assay Kit (R&D Systems, Minneapolis, MN, USA). In brief, 50 ml of cell lysates, which had been derived from 100 mg of total protein, were placed onto 96-well plates, and then incubated at 371C for 2 h with 50 ml of reaction buffer and 5 ml of colorimetric substrate for caspase-3 (DEVD-pNA). Optical density was then read on a microplate reader at a light wavelength of 405 nm.
Measurement of the expression of MMPs
Zymography. The DU-145 cells (2 Â 10 4 cells) were treated with curcumin (1, 10, 15 mg/ml) for 24 h, after which the whole-cell lysates were isolated. Zymography for MMP-2 and MMP-9 zymography was conducted via sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% SDS-PAGE), the gels of which contained 0.1% gelatin. Equal protein amounts (20 mg) from the cell lysates were used in each gel run. After undergoing electrophoresis, the gels were soaked for 2 h in 2.5% Triton X-100 solution, with four washing steps. The gels were then incubated for an additional 72 h at 371C in collagenase buffer supplemented with 50 mM Tris-HCl/ pH 7.6, 200 mM NaCl, 5 mM CaCl 2 , and 0.2 % Brij-35. After incubation, the gels were stained with Coomassie Blue G-250, and then destained. The MMP activity was visualized as white proteolysis bands against the Coomassie blue-stained gel. The molecular weights of these bands were determined by Molecular Weight Standards (Bio-Rad Laboratories, Hercules, CA, USA).
ELISA. The ELISA assays for MMP-2 and MMP-9
were conducted with commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA). In brief, the DU-145 cells (2 Â 10 4 ) were treated with curcumin (0, 25, 50, and 100 mg/ml), after which the cell lysates were transferred to 96-well plates, which had been precoated with antibodies specific for MMP-2 and MMP-9. The cell lysates were then processed in accordance with the manufacturer's instructions. Absorbance was measured on each of the wells at 450 nm, using a microplate reader.
Cell invasion assay. One of the key steps in the metastatic cascade is invasion through the ECM and the basement membrane. Matrigel can be utilized in vitro, as a reconstituted basement membrane with a biologically active ECM. Different curcumin dosages were administered in order to assess the inhibition of cell invasion in the Matrigel system. We conducted migration experiments using the BD BioCoat Matrigel Invasion Chamber (BD Biosciences, Franklin Lakes, NJ, USA), which is comprised of a 24-well BD Falcon TC Companion Plate, with Falcon Cell Culture Inserts, containing PET membranes with 8 mm pores. These membranes were coated with thin layers of Matrigel. In brief, the DU-145 cells (1.5 Â 10 4 cells in 0.5 ml medium/ well), either with or without curcumin, were added to each insert (upper chamber), and the chemoattractants (5% FBS) were placed into each of the wells of a 24-well companion plate (lower chamber). After 24 h of incubation, the cells that invaded through the Matrigel insert membrane were fixed and stained with a Diff-Quik staining kit (BD Biosciences, Franklin Lakes, NJ, USA). The number of cells that invaded from three or more random microscopic fields ( Â 40 magnification) was counted. All of the experiments in this section were conducted in triplicate.
In vivo study
Severe combined immunodeficient (SCID) mice, 6-weekold male, were purchased from Charles River Japan, Inc. (Osaka, Japan), and then maintained in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals. The DU-145 cells were trypsinized, washed in PBS, and then resuspended in Hanks buffered salt solution (HBSS). Only single-cell suspensions exhibiting more than 90% viability, as was confirmed by trypan blue exclusion, were utilized for inoculation. The metastatic DU-145 cell line was isolated from the lung metastasis generated by parental DU-145 cells, which were implanted into the tail veins of SCID mice. The cultured DU-145 cells were then reinjected into the tail veins of SCID mice subsequently to the acquisition of an ex vivo culture of cells which had been obtained from the metastatic nodules. This procedure was repeated four times, resulting in the yield of cell lines with increasing metastatic potential. Then, the DU-145 cells (1 Â 10 6 cells), which had been suspended in 200 ml of HBSS,
Curcumin inhibits MMP in prostate cancer JH Hong et al were subcutaneously injected into the footpads of these mice, using a 27-gauge needle. Purified curcumin (X95% purity) for use in the in vivo study was purchased from the Sigma Chemical Co. (St. Louis, MO, USA). A total of 20 SCID mice, 6 weeks of age, were divided into two subgroups, depending on the curcumin treatment applied. The control group (n ¼ 10) was given a placebo only, a solution containing 0.5% methylcellulose and 0.1% Tween 80, via oral gavage. The experimental group (n ¼ 10) received an equal volume of placebo, mixed with curcumin, at a dosage of 5 mg/kg, via the same gavage method as was used for the control group. All mice continued to receive placebo or curcumin (three times per week) throughout the period of study.
At 4 weeks after the tumor inoculation, the tumorinoculated site in the foot was amputated at the midfemur level in all of the mice. The volumes of the tumors were measured using calipers, and were then calculated according to the formula (larger diameter) Â (smaller diameter) 2 Â 0.52. The caspase-3 and MMP activity were also determined via caspase-3 assay and ELISA in the grown tumors obtained from the implantation sites. At 10 weeks after the tumor cells had been injected into the foot, the mice were killed and the presence of metastasis was macroscopically examined. The numbers of surface metastatic nodules were counted after organs with metastases had been fixed in Bouin's solution. All metastases were verified via histological examinations with hematoxylin and eosin staining. The animal study protocol had all received previous approval by the Institutional Animal Care and Use Committee, of the Samsung Biomedical Research Institute, Korea.
Statistical analysis
All continuous variables were expressed as means7s.d. Wilcoxon rank sum tests and Fisher's exact tests for independent samples were also conducted. A P-value of o0.05 was adopted as the statistical significance level.
Results
In vitro study Curcumin inhibits the proliferation of DU-145 prostate cancer cells. Cellular growth, according to the varying curcumin concentrations applied to the DU-145 cells, is shown in Figure 1a . The curcumin-treated cells manifested dose-dependent reductions in the rate of cellular growth. At a 30 mg/ml curcumin concentration, the curcumin was determined to have induced a 50% reduction in the cell numbers, as compared with the controls, after 24, 48, and 72 h of treatment. We noted only minor changes in cell viability between the cells treated with 60 mg/ml of curcumin and those treated with 120 mg/ml. Cell growth was not determined to have been inhibited along with increases in the curcumin concentrations, up to a maximal concentration of 10 mg/ml.
We also assessed the effects of curcumin with regard to apoptosis via the measurement of caspase-3 activity. As is shown in Figure 1b , the inhibition of programmed cell death occurred in a time-dependent manner, with nontoxic curcumin concentrations (10 mg/ml). These results indicate that curcumin exerts antiproliferative effects against DU-145 prostate cancer cells.
Curcumin reduces MMP-2 and MMP-9 secretion. In order to characterize curcumin's effects on the secretion of MMP, we used zymography to detect the expression of gelatinase, and MMP substrate-linked ELISA was used in the quantitation of MMP-2 and MMP-9 secretion activity. As is shown in Figure 2a , the secretion of the pro-form of MMP-9 (92 kD gelatinase) was reduced significantly. On the other hand, the pro-form of MMP-2 (72 kD gelatinase) was not inhibited to any dramatic extent in the curcumin-treated cells, as compared with untreated cells. However, the results of our enzymatic activity assay revealed that net MMP-2 and MMP-9 secretion exhibited an inverse relationship with curcumin concentrations (Figure 2b ). As the result of treatment with 50 mg/ml of curcumin, we noted reductions in the enzymatic activity of MMP-2 and MMP-9, to 60 and 5% of control levels, respectively. Our findings appear to imply that curcumin elicits a reduction in the secretion of MMP-2 and MMP-9.
Curcumin inhibits the invasiveness of DU-145 prostate cancer cells. We conducted a Matrigel invasion assay in order to assess curcumin's effects on the invasive capacity of the DU-145 prostate cancer cells. After 24 h (Figure 3) . At a 10 mg/ml dose of curcumin, invasive ability was determined to have decreased by 71%, compared to the control.
In vivo study
The mean reduction in the body weights of the control (curcumin-untreated) and experimental (curcumin-treated) animals were determined to be 11.1 and 9.0%, respectively, by the end of the study. Oral treatment with curcumin at a dosage of 5 mg/kg/three times per week was tolerated quite well, with no significant losses in body weight, or other noticeable toxic side effects.
The effects of curcumin on the growth of tumors in the feet of the SCID mice are shown in Figure 4a We also assessed both caspase-3 activity and the enzymatic activity of MMPs, including MMP-2 and MMP-9 at the implanted tumors, in order to verify the in vitro results (Figure 4b and c). Significant differences were determined to exist between the control group and the experimental group, with regard to the activity of caspase-3 and MMPs. These findings suggested that curcumin not only induces apoptosis, but also inhibits MMP secretion within the primary tumor site.
As is shown in Table 1 , we determined there to be no statistically significant differences with regard to the occurrence of lung metastasis between each of the groups. However, the mean numbers of metastatic pulmonary nodules differed significantly between the control group and experimental group (P ¼ 0.001).
Discussion
Although prostate cancer is characterized by fairly slowly growing tumors, and is usually diagnosed in elderly males, the mortality rate of this cancer tends to be higher than that associated with other cancers in Western men. Metastatic prostate cancer has been identified as the most significant cause of prostate cancer death. In order for a metastasis to occur, the metastasis cascade must ensue, and the degradation of the ECM and basement membrane constitute a crucial step in this cascade. Type IV collagen is the principal component of the basement membrane. Thus, the type IV collagenases, MMP-2 and MMP-9, appear to be vitally important with regard to both invasion and metastasis. The results of epidemiologic studies indicate that dietary factors may be the main reason that Western populations run a higher risk of prostate cancer than do Asian populations. 2, 3 Recently, curcumin has become a focus of interest with regard to its possible antitumor effects in prostate cancer. [12] [13] [14] [15] [16] [17] [18] This study shows for the first time, to our knowledge, that curcumin exerts an inhibitory effect on the invasiveness of DU-145 prostate cancer cells, and confirms this via both in vitro and in vivo testing.
Our in vitro results demonstrated that curcumin inhibits cellular proliferation and induces apoptosis in androgen-independent DU-145 prostate cancer cells. In the DU-145 cells, curcumin was shown to induce a 50% reduction in cellular growth between the first and third days after treatment with 30 mg/ml of curcumin. Curcumin was also determined to induce apoptosis, which has been associated with the activation of caspase-3. Caspase-3 is a principal enzyme in the apoptotic cascade. This observation was previously reported in both androgen-dependent and androgen-independent prostate cancer cell lines. 12, 14, 16 Cytochrome c has been determined to function via the formation of a multicomplex, and subsequently initiates a cascade of caspase activations during chemically induced apoptosis. We identified the activation of cytochrome c, caspase-9, and poly ADP-ribose polymerase (PARP) after curcumin treatment via Western blotting (data not shown). We also determined that curcumin treatment of DU-145 cells effected a reduction in MMP-2 and MMP-9 activity in vitro, in a dose-dependent manner. Furthermore, curcumin appears to perform a crucial role in the inhibition of invasive ability, and this was confirmed by Matrigel invasion assay.
Based on the antitumor properties of curcumin evidenced in the in vitro study, we attempted to characterize the effects of a curcumin-supplemented diet on a xenograft model, which had been induced by the implantation of DU-145 cells. Although the overall incidence of tumor development at the implanted site was not determined to have been inhibited by curcumin treatment, we did note that curcumin exerted inhibitory effects on tumor volume and the activity of MMPs. This finding suggested that curcumin alone might inhibit the progression of preexisting tumors, as tumor growth and increased MMP activity are required for the induction of local invasion and further metastasis. A decreasing tendency toward spontaneous lung metastasis after the surgical removal of the initial implanted tumors was Figure 4 The tumor volumes at the implanted sites after 4 weeks of inoculation (a). Highly metastatic potential DU-145 cells (1 Â 10 6 cells) were injected into the footpads of SCID mice. All experimental animals were treated three times per week either with placebo only (control group) or with curcumin (experimental group, 5 mg/kg). The curcumin-treated mice were determined to exhibit significantly lower tumor volumes than did the control group mice. In order to verify the in vitro results, we also measured the activity of caspase-3 (b) and MMPs (c) via caspase-3 assays and ELISA in the grown tumor tissue obtained from the implantation sites. The asterisk indicates the statistically significant differences between the control and experimental groups, and the P-values were calculated via Wilcoxon rank sum tests.
Curcumin inhibits MMP in prostate cancer JH Hong et al noted in the curcumin-treated animals. The numbers of metastatic nodules in the lungs of subjects were reduced by 89% by curcumin treatment, as compared to the untreated group. Therefore, these in vivo results appeared to indicate that curcumin might be intimately involved in tumor progression, or in the early stages of the metastatic cascade. MMP expression in the presence of curcumin was characterized by a more significant inhibition of MMP-9 than MMP-2 in our both in vitro and in vivo tests. However, it remains unclear as to what mechanism is responsible for this difference between the enzymatic activity of MMP-2 and MMP-9. The expression of MMP-9 has been demonstrated to affect hematogenous metastasis in cases of murine prostate cancer. 19 Therefore, curcumin may inhibit pulmonary metastasis as a result of MMP reduction, especially via the suppression of MMP-9 activity.
In this study, we have demonstrated the inhibitory effects exerted by curcumin against the growth and invasiveness of DU-145 prostate cancer cells, both in vitro and in vivo. Our findings demonstrated that the inhibition of tumor cell invasion is the result of reductions in MMP-2 and MMP-9. Curcumin may, then, indeed play a potential role as a chemopreventive and/or adjuvant therapeutic agent in the treatment of prostate cancer, probably as a nontoxic dietary supplement.
